Ceruletide resembles antipsychotics in rats and schizophrenic patients. Preliminary report.
Peptides related to the C-terminal part of cholecystokinin, including ceruletide, were found to be active in a number of behavioral test procedures in rats, predicting antipsychotic action. In a subsequent clinical trial ceruletide was administered intramuscularly in a dose of 40 micrograms twice for 2 consecutive weeks to 6 neuroleptic-treated schizophrenic patients following a single-blind design. In 3 patients, a pronounced long-lasting antipsychotic effect was observed, while in the other 3 the response was less marked. It is suggested that ceruletide may be a potential antipsychotic peptide.
D000818:Animals; D014150:Antipsychotic Agents; D001522:Behavior, Animal / Q000187:drug effects*; D010054:Brief Psychiatric Rating Scale; D002108:Ceruletide / Q000494:pharmacology* / Q000627:therapeutic use; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D002108:Ceruletide